Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Windlas Biotech's Marketable Securities for the quarter that ended in Mar. 2026 was ₹2,783 Mil.
Windlas Biotech's annual Marketable Securities
increased
from Mar. 2024 (₹1,980 Mil) to Mar. 2025 (₹2,389 Mil) and
increased
from Mar. 2025 (₹2,389 Mil) to Mar. 2026 (₹2,783 Mil).
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Windlas Biotech Marketable Securities Related Terms
Windlas Biotech Marketable Securities Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Marketable Securities of ₹2,783 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Marketable Securities of ₹2,783 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Windlas Biotech and its competitors.
Is Windlas Biotech's Marketable Securities too high?
Windlas Biotech's current Marketable Securities is ₹2,783 Mil. Overall, Windlas Biotech has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Marketable Securities compare to ZTS and UTHR?
Windlas Biotech's Marketable Securities of ₹2,783 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Windlas Biotech and its competitors. Windlas Biotech's current Marketable Securities is ₹2,783 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹942.79, compared to a current price of ₹871.55 — trading 7.6% below its estimated fair value. The current Marketable Securities is ₹2,783 Mil. Windlas Biotech's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Marketable Securities is ₹2,783 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹871.55 is trading 7.6% below its estimated GF Value™ of ₹942.79.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Marketable Securities: ₹2,783 Mil
GF Value™: ₹942.79 vs. price of ₹871.55 (7.6% below fair value)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
87GF Score
Get the complete analysis for NSE:WINDLAS
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
